A retrospective study to investigate whether the switch from tenofovir disoproxil fumarate/emtricitabine/rilpivirine to tenofovir alafenamide is associated with weight gain in people living with HIV
Latest Information Update: 15 Apr 2020
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions
Most Recent Events
- 01 May 2020 Results published in the AIDS
- 15 Apr 2020 New trial record